coteau ARQ.

APMD

Apnimed, Inc.
$18.99
+$0.46 (2.48%) Oct 23 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-36%-19%-3%+14%+30%Jul 31Oct 23Sep 1152w low $16.12
APMDSPY
Wall St. Highest PT $60.00 (+216.0%) Wall St. Avg PT $50.33 (+165.1%)
$17$33$49$66$82POC $29Hi $60Avg $50
Underwater Drawdown %Max DD -49.0%Current -41.7%
0.0%-49.0%
Relative Strength vs SPY-26.0% vs SPYUnderperforming
+42%0%-42%
1W
+$1.23 (6.93%)
1M
−$3.50 (15.56%)
3M
–
6M
–
YTD
–
1Y
–

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Strong Buy
3 analysts · mean score 1.00
1 = Strong Buy · 5 = Sell
Wall Street consensus
Analyst price targets
Current price$18.99
Average target$50.33
+$31.34 (+165.1%) upsideaverage target vs current price
CurrentAverageMedian
Low$41.00
Median$50.33
High$60.00
12-month Wall Street target range
Recent analyst rating changes · 4
Initiated
2026-08-25 · LifeSci Capital started covering APMD at Outperform
Initiated
2026-08-25 · Cantor Fitzgerald started covering APMD at Overweight
Initiated
2026-08-25 · Evercore ISI Group started covering APMD at Outperform
Initiated
2026-08-25 · B of A Securities started covering APMD at Buy
All analyst rating changes ›

Third-party ratings, not Coteau's views.

Key stats & company

Market value$790.6M
P/E (last 12 months)2.6
P/E (next 12 months, estimated)-4.8
52-week range$16.12 – $35.29
Revenue growth (latest quarter vs a year ago)-29.4%
Dividend yieldNo dividend
Analyst consensusStrong Buy (3)
Average analyst price target$50.33 (+165%)

What they do

Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. It offers AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Healthcare · Biotechnology
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for APMD yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 Coteau Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 Coteau Physical AI Grid & Power
Outside this model's universe or screens
 Coteau Long Book
Not in the current book

Earnings & events

APMD earningsNext report in 17 days
Next report
Wed Nov 11, 2026Time not confirmed
EPS consensus-$0.60 range -$0.61–-$0.59
Revenue consensus$0 3 analysts
Last 1 quarters · EPS vs estimate
Sep 8, 2026-$0.42est -$0.34−22.5%Below estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · refreshed 2026-10-24 02:42:05 ET
26-09-0.420.00
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$12.1M–
2026-03-31$84.8M–
2025-06-30$17.1M–
2025-03-31$3.1M–

News & catalysts

More news
What iShares Russell 2000 Index Fund (IWM) Bought: APNIMED Leads on Oct. 15
GuruFocus.com · Oct 19
iOnctura appoints Paul Sekhri as Chair of its Board of Directors
GlobeNewswire · Oct 15
Apnimed to Present Five Abstracts, Including Two Late-Breakers at CHEST 2026
GlobeNewswire · Oct 12
Bank of America Puts These 2 Under-the-Radar IPO Stocks on Its Buy List
TipRanks · Oct 06
Apnimed, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · Oct 02
Rating changes
Initiated
2026-08-25 · LifeSci Capital started covering APMD at Outperform
Initiated
2026-08-25 · Cantor Fitzgerald started covering APMD at Overweight
Initiated
2026-08-25 · Evercore ISI Group started covering APMD at Outperform
Initiated
2026-08-25 · B of A Securities started covering APMD at Buy

Third-party analyst actions, not Coteau's views. All rating changes

Stats refreshed 2026-10-24 02:42:05 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, Coteau model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

coteau

Free to use. No card, no ads, no auto-renew.

Independent research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026